MIF Antagonist, ISO-1 manufacturers
- MIF Antagonist, ISO-1
-
- $0.00 / 1kg
-
2025-04-04
- CAS:478336-92-4
- Min. Order: 1kg
- Purity: 98%
- Supply Ability: 1Ton
- ISO-1
-
- $39.00 / 2mg
-
2024-11-19
- CAS:478336-92-4
- Min. Order:
- Purity: 98.56%
- Supply Ability: 10g
|
| | MIF Antagonist, ISO-1 Basic information |
| Product Name: | MIF Antagonist, ISO-1 | | Synonyms: | MIF Antagonist, ISO-1;Methyl 2-(3-(4-hydroxyphenyl)-4,5-dihydroisoxazol-5-yl)acetate;ISO-1;MIF Antagonist;4,5-Dihydro-3-(4-hydroxyphenyl)-5-isoxazoleacetic acid methyl ester;ISO-1
(ISO 1;ISO 1;ISO1;MIF ANTAGONIST;5-Isoxazoleacetic acid, 4,5-dihydro-3-(4-hydroxyphenyl)-, methyl ester | | CAS: | 478336-92-4 | | MF: | C12H13NO4 | | MW: | 235.24 | | EINECS: | | | Product Categories: | | | Mol File: | 478336-92-4.mol |  |
| | MIF Antagonist, ISO-1 Chemical Properties |
| Melting point | 114 °C | | Boiling point | 365.0±48.0 °C(Predicted) | | density | 1.30±0.1 g/cm3(Predicted) | | storage temp. | Keep in dark place,Sealed in dry,Store in freezer, under -20°C | | solubility | Soluble in DMSO. | | pka | 9.22±0.30(Predicted) | | form | Light yellow crystalline solid. | | color | Off-white | | Sensitive | Light Sensitive | | Stability: | Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 2 months. |
| | MIF Antagonist, ISO-1 Usage And Synthesis |
| Description | ISO-1 (478336-92-4) is an antagonist of macrophage migration inhibitory factor (MIF, a pro-inflammatory cytokine). Displays anti-inflammatory activity. Increases survival in severe sepsis.1 Inhibits airway remodeling in mouse asthma model.2 ISO-1 also blocks MIF-induced autophagy.3?Active in cellular and mouse models. | | Uses | MIF Antagonist, ISO-1 inhibits MIF dopachrome tautomerase activity by binding to its catalytic active site (IC50 = 7 μM for D-dopachrome tautomerase) and suppresses the production of TNFα, PGE2 and COX-2 in human monocytes and arachidonic acid in RAW 264.7 macrophages. MIF Antagonist, ISO-1 has been shown to exhibit antidiabetogenic properties in immunoinflammatory diabetic mouse model. | | in vivo | ISO-1 (injected intraperitoneally; 3.5-35 mg/kg; twice daily; 2 weeks) improves the survival rate from lethal endotoxemia and shows the anti-inflammatory effect[2].
ISO-1 (intraperitoneal injection; 35 mg/kg; twice daily; 3 days) causes a significant reduction in average implant size and decreases Flk1 expression in implants[3]. | Animal Model: | C57Bl/6 MIF+/+ and MIF–/– mice[2] | | Dosage: | 3.5-35 mg/kg | | Administration: | Injected intraperitoneally; 3.5-35 mg/kg; twice a day ; 2 weeks | | Result: | Was protective against lethal sepsis. |
| Animal Model: | Female C57BL/6-Tg(ACTB-EGFP)1Osb/J mice[3] | | Dosage: | 35 mg/kg | | Administration: | Intraperitoneal injection; 35 mg/kg; twice daily; 3 days | | Result: | Reduced average endometriotic implant size. |
| | storage | Store at +4°C | | References | 1) Al-Abed et al. (2005), ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis; J. Biol. Chem., 280
2) Chen et al. (2010), ISO-1, a macrophage migration inhibitory factor antagonist, inhibits airway remodeling in a murine model of chronic asthma; Mol. Med., 16 400
3) Chuang et al. (2012), Macrophage migration inhibitory factor induces autophagy via reactive oxygen species generation; PLoS One, 7 e37613 |
| | MIF Antagonist, ISO-1 Preparation Products And Raw materials |
|